Physician profile
Abigail Cruz
NPI 1407116130
$1,233.01
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.02 · 2020: $48.85 · 2021: $148 · 2022: $147 · 2023: $400 · 2024: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $323.19 | 2023-2024 | |
| Mirati Therapeutics, INC. | $198.93 | 2023-2024 | Krazati |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2023 | Enhertu |
| Genzyme Corporation | $82.62 | 2020-2023 | |
| Emmaus Medical, INC. | $66.69 | 2022-2023 | Endari |
| Genentech USA, INC. | $63.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $62.44 | 2021-2023 | |
| Abbvie INC. | $55.12 | 2021 | |
| Medunik USA INC. | $49.23 | 2024 | Siklos |
| Alexion Pharmaceuticals, INC. | $46.11 | 2019-2022 | |
| Amgen INC. | $45.14 | 2021-2022 | |
| Celgene Corporation | $20.92 | 2019 | |
| Ucb, INC. | $20.70 | 2021 | |
| Duchesnay USA Incorporated | $20.28 | 2023 | Siklos |
| Greenwich Biosciences, INC. | $19.85 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.71 | 2022 | |
| Pfizer INC. | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.